thelancet.com
Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, co...
Iberdomide, daratumumab, and dexamethasone significantly improved MRD-negative complete
response compared with daratumumab, bortezomib, and dexamethasone. The most common
grade 3 or grade 4 adverse ev...